This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): TG100-115
Description: TG100-115 is an inhibitor of PI3 kinase, an enzyme that influences a wide variety of cellular functions: cell growth, differentiation and survival, glucose metabolism and cytoskeletal organization. TG100-115 is thought to suppress vascular leakage (edema) and reduce infarct size in heart attacks.
Deal Structure: TG100-115 was originally developed by TargeGen.
In June 2010, sanofi-aventis announced that it signed an agreement for the acquisition of TargeGen. Under the terms of the agreement, sanofi-aventis will make an upfront payment of US $75 million upon closing of the transaction. Further milestones payments will occur at different stages of development of TargeGen's lead product, TG 101348. The total amount of all payments, including the upfront payment, could reach US $560 million.
Pink Sheet Weekly Trademark Review Sept. 9, 2014
Pink Sheet Weekly Trademark Review July 22, 2014
Additional information available to subscribers only: